Evidence map›Paper›PMID 38629862›Full record

ArticleBiomarkers in medicine2024

PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer.

Hai Zeng, Qian Wang, Ying Xiang, Yameng Yang, Xia Tu, Hui He, Shuang Li, Weijia Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hai ZengDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Qian WangDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Ying XiangLaboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 434000, Hubei, China.
Yameng YangDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Xia TuDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Hui HeDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Shuang LiDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Weijia ZhangDepartment of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.ORCID 0009-0004-6986-6985
Yangtze University · CN

Funding

Heath and Family Planning Commission of Hubei Province WJ2018H203the First Affiliated Hospital of Yangtze University 2022DIF01the Joint Fund project of Yangtze University WJ2019-22
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colorectal NeoplasmsNeoplasm StagingProtein Serine-Threonine KinasesAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedPolo-like KinasesPrognosisBiomarkers, TumorPLK3 protein, humanPolo-like KinasesProtein Serine-Threonine KinasesTumor Suppressor Proteinsclinicopathological featurescolorectal cancerdisease-free survivaloverall survivalPLK3

Identifiers

PMID38629862
PMCPMC11216246
OpenAlexW4394873010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.